A NEW DAWN

in disease early interception

Featured

MiRXES Launches Project CADENCE for Multi-Cancer Screening Test Development

MiRXES announced today that it has launched Project CADENCE (CAncer Detected Early caN be CurEd), the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers.

Learn More

MiRXES Opens Southeast Asia’s First Industry 4.0 In Vitro Diagnostic Manufacturing Facility

MiRXES has opened the first industry 4.0 (i4.0) in vitro diagnostic (IVD) manufacturing facility in Southeast Asia. This S$8 million facility at JTC MedTech Hub is the largest i4.0 IVD manufacturing site at in Southeast Asia at 15,000 square feet.

Learn More

MiRXES’s Founders Named EY Entrepreneur Of The Year 2021 Singapore

MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.

Learn More

Our Science & Pipeline

At MiRXES, we harness the power of RNA to deliver early, actionable and personalized diagnoses across the care continuum to improve and save lives. Prevention is better than cure.

With early detection, mitigating risk factors and implementing prevention strategies, most cancer deaths can be prevented.

Our science opens us to a world without late-stage cancer diagnoses. This is how we improve and save lives.

MiRXES endeavors to be at the forefront of disease early detection and interception.

Delivering Our Solutions

One in four people has cancer in the world today. At MiRXES, we know the importance of science in the fight against cancer.

We understand that to make the most impact in improving and saving lives, we must translate and deliver our innovative solutions from the lab to clinic.

Read more about how our solutions that range from industry-leading discovery tools and services to diagnostic tests for cancer, cardiovascular, metabolic and infectious diseases, and precision oncology can enable you to act sooner – when it matters most.